DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Tolcapone

Tolcapone

  • Therapy for Movement Disorders

    Therapy for Movement Disorders

  • (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al

  • Summary of Drug Limitations Mary C

    Summary of Drug Limitations Mary C

  • Safinamide: an Add-On Treatment for Managing Parkinson's Disease

    Safinamide: an Add-On Treatment for Managing Parkinson's Disease

  • Opicapone for the Management of End-Of-Dose Motor Fluctuations in Patients with Parkinson’S Disease Treated with L-DOPA

    Opicapone for the Management of End-Of-Dose Motor Fluctuations in Patients with Parkinson’S Disease Treated with L-DOPA

  • 207145Orig1s000

    207145Orig1s000

  • 212489Orig1s000 SUMMARY REVIEW

    212489Orig1s000 SUMMARY REVIEW

  • A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice

    A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice

  • Opicapone Capsules for the Treatment of Parkinsons Disease (Pd) in Adult Patients Recommended for Restricted Use (Amber Initiation)

    Opicapone Capsules for the Treatment of Parkinsons Disease (Pd) in Adult Patients Recommended for Restricted Use (Amber Initiation)

  • Tolcapone Shared Care Guideline

    Tolcapone Shared Care Guideline

  • Parkinson's Disease with End-Of-Dose Motor Fluctuations: Opicapone

    Parkinson's Disease with End-Of-Dose Motor Fluctuations: Opicapone

  • Therapeutic Drug Guidelines for ATCS

    Therapeutic Drug Guidelines for ATCS

  • TASMAR* (Tolcapone) RATIONALE for INCLUSION in PA PROGRAM

    TASMAR* (Tolcapone) RATIONALE for INCLUSION in PA PROGRAM

  • Terms Moving from Scrs 2018 Mesh to Descriptors in 2019

    Terms Moving from Scrs 2018 Mesh to Descriptors in 2019

  • Clinical Pharmacology & Toxicology Pearl of the Week

    Clinical Pharmacology & Toxicology Pearl of the Week

  • (12) United States Patent (10) Patent No.: US 9,101,663 B2 Yacoby-Zeevi Et Al

    (12) United States Patent (10) Patent No.: US 9,101,663 B2 Yacoby-Zeevi Et Al

  • Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline

    Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline

  • Safinamide (Xadago) Reference Number: ERX.NPA.45 Effective Date: 09.01.17 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log

    Safinamide (Xadago) Reference Number: ERX.NPA.45 Effective Date: 09.01.17 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log

Top View
  • Therapeutic Drug Class
  • TASMAR® (Tolcapone) TABLETS
  • Parkinson's Disease Medications
  • Medications Approved for the Treatment of Parkinson's Disease In
  • Practical Guidelines for Management of Parkinson Disease
  • The Effect of Nicotine in Combination with Various Dopaminergic Drugs on Nigrostriatal Dopamine in Rats
  • Psychopharmacologic Approaches to Attention, Alertness, and Initiation After Brain Injury Mel B
  • Medication Glossary- Drug Classes and Medication
  • Entacapone Is Beneficial in Both Fluctuating and Non-Fluctuating
  • A Treatment Guide to Parkinson's Disease
  • Tasmar, INN-Tolcapone
  • New Zealand Data Sheet Tasmar®
  • Drug Benefit Guide
  • Medical Management of Parkinson's Disease
  • LMMG New Medicine Recommendation
  • Medical Necessity Criteria for Pharmacy Edits, 5.01.605
  • Inbrija (Levodopa) Nourianz (Istradefylline) Effective 09/01/2020
  • XADAGO™ (Safinamide) Oral


© 2024 Docslib.org    Feedback